Aethlon Medical, Inc. (OTCMKTS:AEMD) Reaches A 52 Week High

[[tagnumber 0]][[tagnumber 1]]We have seen quite a lot of interest in the stock of Aethlon Medical, Inc. (OTCMKTS:AEMD) in the past month, as the ebola craze high the world and many biotech companies saw wide investor interest.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Unlike some of the others that decided they can boost their tickers, [[tagnumber 6]]AEMD [[tagnumber 7]]actually has a product that was developed as a broad spectrum countermeasure against pandemic threats and chronic viral pathogens. It is called the Hemopurifier® and was successfully used for the treatment of a Ugandan physician in The Frankfurt University Hospital.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Let’s not forget that [[tagnumber 6]]AEMD [[tagnumber 7]]is also in a decent financial state as their most recent report showed. Here are the numbers of prime interest contained in the balance sheet for the period ended September 30.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 17]] [[tagnumber 18]]cash: $526 thousand[[tagnumber 19]] [[tagnumber 18]]current assets: $892 thousand[[tagnumber 19]] [[tagnumber 18]]total assets: $1 million[[tagnumber 19]] [[tagnumber 18]]current liabilities: $3.38 million[[tagnumber 19]] [[tagnumber 18]]total liabilities: $4.37 million[[tagnumber 19]] [[tagnumber 18]]quarterly revenues: $479 thousand[[tagnumber 19]] [[tagnumber 18]]net loss: $847 thousand[[tagnumber 19]] [[tagnumber 32]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]The good news is that the company managed to increase its revenues compared to the second quarter of the year. It was still, however, lower than that of the same period in 2013, but at least so was the net loss.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]In the same time, the liabilities have remained almost the same and have even been a bit lowered. These results, coupled with the good outcome of the treatment in Germany were sure to make an impact on the ticker.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]In Friday’s session [[tagnumber 6]]AEMD [[tagnumber 7]]climbed some 23.40% and recorded a total volume of 8.68 million shares that generated $2.56 million in daily trade value. The start of this weak was even greater, after the ticker jumped up another 28.44%, to a close at $0.42. This time investor interest was even greater and the 32.46 million shares that changed their owners generated a massive $13.55 million in daily dollar volume.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]That way it reached a new 52 week high, but can it holds its positions. The current market cap of [[tagnumber 6]]AEMD [[tagnumber 7]]is sitting at $123 million and the company seems to have a sound product that can be used for the treatment of various dreadful diseases. It is still, however, in the process of receiving and Investigational Device Exemption approval from the Food and Drug Administration, which might take some time.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]In any case, be sure to always do your due diligence and weigh out the risks before making any investment decisions.[[tagnumber 2]]